Active	Status	Sponsor type	Region	Phase	Filter
9 Active 4 Inactive 13 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   - « July » « 2025 » M T W T F S S 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3   Show only changed items Enrollment:

Advanced Filters

9 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ANG-3070 / Elicio Therap
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease	Recruiting	2	100	US, RoW	ANG-3070, Placebo	Angion Biomedica Corp, Angion Biomedica Corp.	Glomerular Disease, Proteinuria	07/23	08/23
ANG3070-IPF-102, NCT05387785: Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis	Not yet recruiting	1b	20	NA	ANG-3070, Placebo	Angion Biomedica Corp	Idiopathic Pulmonary Fibrosis (IPF)	11/22	11/22
terevalefim (ANG-3777) / Elicio Therap, CSL Behring
NCT02474667: Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney Oct 2021 - Dec 2021 : Data from trial for transplant-associated acute kidney injury (delayed graft function)	Active, not recruiting	3	253	US	ANG-3777, Hepatocyte growth factor mimetic, BB3, Placebo, Normal saline	Angion Biomedica Corp, CTI Clinical Trial and Consulting Services	Delayed Graft Function	09/21	09/21
NCT04459676: Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia	Active, not recruiting	2	100	RoW	Standard of Care (SOC) + ANG-3777, BB3, Hepatocyte growth factor mimetic, Standard Of Care (SOC) + Placebo	Angion Biomedica Corp, CTI Clinical Trial and Consulting Services	COVID-19, Pneumonia	04/21	04/21
NCT02771509: Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass Apr 2021 - Jun 2021 : Data from trial for acute kidney injury after cardiac surgery	Active, not recruiting	2	275	Canada, US, RoW	ANG-3777, Hepatocyte growth factor mimetic, Placebo, Normal Saline	Angion Biomedica Corp, Everest Clinical Research, CTI Clinical Trial and Consulting Services, Clinical Accelerator	Acute Kidney Injury	08/21	08/21
NK05: Phase I Clinical Study Using an Antifibrotic Drug	Temporarily Not Available	1	0	RoW	BB 3	Angion Biomedica Corporation	Hepatic fibrosis
NCT04931524: A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777	Recruiting	1	6	Europe	carbon-14-[14C]-ANG-3777, Hepatocyte growth factor mimetic	Angion Biomedica Corp, Quotient Sciences	Healthy	06/21	06/21
NCT04898907: Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval	Not yet recruiting	1	48	US	ANG-3777 (Therapeutic Dose), Hepatocyte growth factor mimetic, ANG-3777 (Supra-therapeutic Dose), Placebo, Normal Saline, Moxifloxacin Hydrochloride	Angion Biomedica Corp, Quotient Sciences	Healthy Volunteer	09/21	09/21
NCT04958187: Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects	Not yet recruiting	1	16	US	ANG-3777, Hepatocyte growth factor mimetic	Angion Biomedica Corp, Nucleus Network Ltd	Hemodialysis	10/21	10/21
ANG-3281 / Elicio Therap
No trials found
ANG-3586 / Elicio Therap
No trials found
ANG-4021 / Elicio Therap
No trials found
ANG-2684 / Elicio Therap
No trials found
ANG-3038 / Elicio Therap
No trials found

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
ANG-3070 / Elicio Therap
NCT04939116 / 2021-006579-41: Study of Safety and Efficacy of ANG-3070 in Chronic Kidney Disease	Recruiting	2	100	US, RoW	ANG-3070, Placebo	Angion Biomedica Corp, Angion Biomedica Corp.	Glomerular Disease, Proteinuria	07/23	08/23
ANG3070-IPF-102, NCT05387785: Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis	Not yet recruiting	1b	20	NA	ANG-3070, Placebo	Angion Biomedica Corp	Idiopathic Pulmonary Fibrosis (IPF)	11/22	11/22
terevalefim (ANG-3777) / Elicio Therap, CSL Behring
NCT02474667: Reduce the Severity of DGF in Recipients of a Deceased Donor Kidney Oct 2021 - Dec 2021 : Data from trial for transplant-associated acute kidney injury (delayed graft function)	Active, not recruiting	3	253	US	ANG-3777, Hepatocyte growth factor mimetic, BB3, Placebo, Normal saline	Angion Biomedica Corp, CTI Clinical Trial and Consulting Services	Delayed Graft Function	09/21	09/21
NCT04459676: Study to Assess Efficacy and Safety Relative to Standard of Care in Patients With COVID-19 Pneumonia	Active, not recruiting	2	100	RoW	Standard of Care (SOC) + ANG-3777, BB3, Hepatocyte growth factor mimetic, Standard Of Care (SOC) + Placebo	Angion Biomedica Corp, CTI Clinical Trial and Consulting Services	COVID-19, Pneumonia	04/21	04/21
NCT02771509: Study to Prevent Acute Kidney Injury After Cardiac Surgery Involving Cardiopulmonary Bypass Apr 2021 - Jun 2021 : Data from trial for acute kidney injury after cardiac surgery	Active, not recruiting	2	275	Canada, US, RoW	ANG-3777, Hepatocyte growth factor mimetic, Placebo, Normal Saline	Angion Biomedica Corp, Everest Clinical Research, CTI Clinical Trial and Consulting Services, Clinical Accelerator	Acute Kidney Injury	08/21	08/21
NK05: Phase I Clinical Study Using an Antifibrotic Drug	Temporarily Not Available	1	0	RoW	BB 3	Angion Biomedica Corporation	Hepatic fibrosis
NCT04931524: A Study to Assess the Absorption, Metabolism and Excretion of [14C]-ANG-3777	Recruiting	1	6	Europe	carbon-14-[14C]-ANG-3777, Hepatocyte growth factor mimetic	Angion Biomedica Corp, Quotient Sciences	Healthy	06/21	06/21
NCT04898907: Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval	Not yet recruiting	1	48	US	ANG-3777 (Therapeutic Dose), Hepatocyte growth factor mimetic, ANG-3777 (Supra-therapeutic Dose), Placebo, Normal Saline, Moxifloxacin Hydrochloride	Angion Biomedica Corp, Quotient Sciences	Healthy Volunteer	09/21	09/21
NCT04958187: Study to Evaluate the Pharmacokinetics of ANG-3777 in Hemodialysis Subjects	Not yet recruiting	1	16	US	ANG-3777, Hepatocyte growth factor mimetic	Angion Biomedica Corp, Nucleus Network Ltd	Hemodialysis	10/21	10/21
ANG-3281 / Elicio Therap
No trials found
ANG-3586 / Elicio Therap
No trials found
ANG-4021 / Elicio Therap
No trials found
ANG-2684 / Elicio Therap
No trials found
ANG-3038 / Elicio Therap
No trials found